Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Directors
29.7.2021 13:30:00 EEST | Business Wire | Press release
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced the expansion of the company’s board of directors with key appointments, including:
- Tom Heyman, former president of the Johnson & Johnson Development Corporation (JJDC)
- Anand Shah, M.D., former deputy commissioner for medical and scientific affairs at the U.S. Food and Drug Administration (FDA)
- Michael Wyzga, president of MSW Consulting, Inc.
“I am thrilled to welcome Tom, Anand and Mike to our board of directors, bringing unmatched expertise from their respective industry roles, and who join at a critical time as we prepare for potential commercialization of ADG20 to combat COVID-19, including rapidly emerging variants,” said Rene Russo, Adagio co-founder and chair of the board of directors. “Spanning his 37-year career with Johnson & Johnson, Tom held a diverse range of leadership roles across R&D, business development, corporate strategy and equity investments. As the deputy commissioner at the FDA until January 2021, Anand led consensus medical and scientific policy development and, during the COVID-19 pandemic, worked across the federal government and with the private sector to advance the development of vaccines and treatments.”
Jane Henderson, Adagio’s chief financial officer added, “Financial strength and discipline are of the utmost importance to our success as we advance several clinical trials with ADG20. We are thrilled to welcome Mike to our board, who brings years of experience leading exceptional financial operations at both public and private companies within the pharmaceutical industry. We look forward to partnering with him, as well as Tom and Anand, to benefit from their invaluable insights into clinical development, financial best practices, regulatory strategy, policy engagement and commercial execution, so that we may address this ongoing global pandemic today.”
Tom Heyman has a long-standing track record in the biopharmaceutical industry, with particular experience in business development and venture capital. He most recently served as president of JJDC, the venture capital group within Johnson & Johnson, where he managed approximately $1.5 billion of capital and oversaw investments in over 120 companies. Prior to his role at JJDC, Mr. Heyman spent 23 years leading business development for Johnson & Johnson’s pharmaceutical group, Janssen, where he was involved in hundreds of licensing and M&A transactions. Under his leadership, major licensing transactions were executed for products like Levaquin, Aciphex, Incivo, Olysio, Velcade, Invokana, Imbruvica, Xarelto and Darzalex, many of which have achieved sales of over $1 billion annually. Also, during his tenure, he led Janssen Belgium through a significant reorganization and implemented a new strategic plan for the site with a major emphasis on external innovation and value creation. Mr. Heyman graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.
Anand Shah, M.D., is a U.S. health policy leader who recently served as the deputy commissioner for medical and scientific affairs at the FDA. Dr. Shah led medical and scientific policy development for high priority programs including Advanced Manufacturing, the Coronavirus Treatment Acceleration Program, COVID-19 vaccine development, and decentralized clinical trials. Under his leadership, FDA initiated the Pandemic Recovery and Preparedness Plan (PREPP) to strengthen the response to the COVID-19 pandemic and resiliency for future public health emergencies. Dr. Shah represented FDA with top-level policy makers of the White House and Cabinet, Congress, and state and local governments. He previously served in senior leadership at the Centers for Medicare & Medicaid Services, both as senior medical advisor and chief medical officer of the Center for Medicare & Medicaid Innovation. Dr. Shah was chief resident during his radiation oncology residency at Columbia University. He concurrently earned his M.D. from the University of Pennsylvania and an M.P.H. in health care management and policy from the Harvard School of Public Health. Dr. Shah has an economics degree from Duke University.
Michael Wyzga is the president of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting, a position he has held since November 2013. Prior to that, he served as president, chief executive officer and a member of the board of directors of Radius Health, Inc. From 1993 to 2011, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as executive vice president, finance and as chief financial officer. During his time with Genzyme, Mr. Wyzga played key roles in the successful development and commercialization of a number of important therapies, including Cerezyme for Gauche disease, Fabrazyme for Fabry’s disease, Renagel for use in the treatment of dialysis patients and Campath for chronic lymphocytic leukemia. Mr. Wyzga has served on a number of public company boards, including at Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, LogicBio Therapeutics, Akebia Therapeutics, Inc., Idenix Pharmaceuticals, Inc., Prosensa Holding B.V. Mr. Wyzga received an MBA from Providence College and a B.S. from Suffolk University.
About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005405/en/
Contact information
Media:
Dan Budwick, 1AB
Dan@1abmedia.com
Investors:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 18:30:00 EET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 17:24:00 EET | Press release
When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technology risks, and ensure regulatory compliance. “Over the last 30 years, COBIT has been a trusted framework for countless organizations, providing a holistic, stru
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 17:04:00 EET | Press release
North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioenergy with carbon capture and storage (BECCS) projects selected through the competitive process, following a r
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 16:32:00 EET | Press release
Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally required paying to reach them again. Meanwhile, direct web sales have become a major revenue ch
From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 16:10:00 EET | Press release
The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
